Cognitive processes of apathy in Huntington’s disease show high sensitivity to disease progression

• Published in: Clinical parkinsonism & related disorders 2022-01, Vol.7, p.100168-100168, Article 100168
• Main Authors: Hare, Emily, Bachoud-Lévi, Anne-Catherine, Reilmann, Ralf, Craufurd, David, Busse, Monica, Rosser, Anne, McLauchlan, Duncan
• Format: Article
• Language: English
• Subjects: Biomarker; Clinical trials; Cognition; Huntington’s Disease; Neuropsychiatry; Short Communications
• ISSN: 2590-1125; 2590-1125
• DOI: 10.1016/j.prdoa.2022.100168

•Deficits in option generation are sensitive to disease progression in HD.•Learning from negative outcomes is associated with apathy in HD.•A novel task of creativity shows promise as a HD biomarker. Disease-modifying treatments for Huntington’s disease (HD) are entering clinical trials: there is a pressing need for objective outcome measures of disease progression. Our previous work showed an association between 2 novel, objective cognitive tasks and apathy - a core feature of disease progression in HD. Evaluate the longitudinal validity and sensitivity of the novel Persistence and Maze tasks to assess their utility as clinical outcome measures in HD. 83 participants positive for the HD gene and 54 controls performed a battery of established and novel tools, at baseline and 12 month follow up. The Maze task was found to be the most sensitive measure of change at 12 months, including the current gold-standard measure (the composite disease progression score). The Maze task has potential as a novel outcome measure of disease progression in HD and may have utility in other major neurodegenerative diseases.